Novo Nordisk shares rise 5% after Wegovy obesity pill has ‘solid’ launch
Shares of Novo Nordisk rose more than 5% after early data showed a strong initial U.S. launch for its new GLP-1 weight-loss pill, Wegovy. Analysts described the early prescription numbers as a “solid start,” with estimates ranging from about 3,100 to more than 4,000 prescriptions filled in the first full week. The early momentum boosts Novo Nordisk’s efforts to regain market share from rival Eli … Continue reading Novo Nordisk shares rise 5% after Wegovy obesity pill has ‘solid’ launch
